Exploring the role of miRNAs in the diagnosis of MODY3

dc.authorid0009-0001-5651-1331
dc.authorid0000-0003-0103-5734
dc.authorid0000-0002-2267-2110
dc.authorid0000-0003-0504-5091
dc.contributor.authorBaltaci, Oguzhan Fatih
dc.contributor.authorColakoglu, Seyma
dc.contributor.authorGullu Amuran, Gokce
dc.contributor.authorAydin, Neslihan
dc.contributor.authorSargın, Mehmet
dc.contributor.authorKarabay, Arzu
dc.contributor.authorYilmaz, Temel
dc.date.accessioned2025-05-10T19:59:25Z
dc.date.issued2018
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground/aim: MODY3 associated with HNF1A is the most common form of MODY and is clinically misdiagnosed as type 1 diabetes due to similar clinical symptoms. This study aimed to analyze the role of HNF1A-regulated miRNAs as a biomarker in the diagnosis of MODY3. Materials and methods: MIN6 cells were transfected with the HNF1A cDNA expression vector for overexpression or with siRNA specific to HNF1A to silence its expression. The HNF1A-regulated miRNAs were determined by RNA-Seq of the total RNA extract. Expressions of the candidate miRNAs in blood samples of MODY3, type 1 diabetes, and type 2 diabetes patients and in healthy subjects were compared statistically by Mann-Whitney U tests. Results: This study revealed the presence of 238 known HNF1A-regulated miRNAs in MIN6 cells. miR-129-1-3p, miR-200b-3p, and miR-378a-5p were selected as candidate miRNAs. The expression level of miR-378a-5p significantly decreased in type 2 diabetes and MODY3 patients, while miR-200b-3p expression was significantly decreased only in MODY3 patients. Conclusion: Although further studies with larger numbers of patients are required, this study demonstrated that the expression levels of miR-200b-3p and miR-378a-5p decrease in MODY3 patients and suggests that miR-200b-3p is an especially strong candidate to use clinically for selecting suspected MODY3 patients.
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [113S217]
dc.description.sponsorshipThis study was supported by the Scientific and Technological Research Council of Turkey (TUBITAK Grant Number: 113S217).
dc.identifier.doi10.3906/sag-1711-98
dc.identifier.endpage+
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue3
dc.identifier.pmid29916222
dc.identifier.scopus2-s2.0-85048612502
dc.identifier.scopusqualityQ1
dc.identifier.startpage620
dc.identifier.trdizinid323714
dc.identifier.urihttps://doi.org/10.3906/sag-1711-98
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/323714
dc.identifier.urihttps://hdl.handle.net/20.500.14730/13835
dc.identifier.volume48
dc.identifier.wosWOS:000435653900025
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectBiomarker
dc.subjectdiabetes
dc.subjectmiRNA
dc.subjectMODY3
dc.subjectmiR-200
dc.subjectmiR-378
dc.titleExploring the role of miRNAs in the diagnosis of MODY3
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
13835.pdf
Boyut:
3.98 MB
Biçim:
Adobe Portable Document Format